MicroBiome Therapeutics Launches Clinically-Tested Dietary Supplement Engineered to Modulate the Gut Microbiome

April 23, 2018

MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness, today announced the launch of BiomeBliss™, a patented, first-in-class prebiotic dietary supplement specifically developed to support a healthy gastrointestinal (GI) microbiome. Developed by pioneering researchers and entrepreneurs, BiomeBliss nourishes, shifts and protects the GI microbiome ‒ the trillions of gut bacteria that affect health.

Click here to read the full story on Business Insider.

Pin
Share
Tweet
+1
Share
0 Shares